Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial,medRxiv - Infectious Diseases

当前位置： X-MOL 学术 › medRxiv. Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
medRxiv - Infectious Diseases Pub Date : 2021-09-12 , DOI: 10.1101/2021.09.07.21263206
Peter Bergman , Ola Blennow , Lotta Hansson , Stephan Mielke , Piotr Nowak , Puran Chen , Gunnar Soderdahl , Anders Osterborg , C.I. Edvard Smith , David Wullimann , Jan Vesterbacka , Gustaf Lindgren , Lisa Blixt , Gustav Friman , Emilie Wahren Borgstrom , Anna Nordlander , Angelica Cuapio Gomez , Mira Akber , Davide Valentini , Anna-Carin Norlin , Anders Thalme , Gordana Bogdanovic , Sandra Muschiol , Peter Nilsson , Sophia Hober , Karin Lore , Margaret Sallberg Chen , Marcus Buggert , Hans-Gustav Ljunggren , Per Ljungman , Soo Aleman ,

Background Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate the safety and efficacy after two doses of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls.

中文翻译：

在一项前瞻性开放标签临床试验中，针对 SARS-CoV-2 的 mRNA BNT162b2 疫苗在五组免疫功能低下患者和健康对照中的安全性和有效性

背景免疫功能低下疾病患者主要被排除在针对 COVID-19 的疫苗接种临床试验之外。因此，这项前瞻性临床试验的目的是在选定的五组免疫功能低下患者和健康对照组中研究两剂 BNT162b2 mRNA 疫苗接种后的安全性和有效性。

更新日期：2021-09-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文